Parallel Advisors’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $36.8K | Sell |
2,046
-491
| -19% | -$9.29K | ﹤0.01% | 2328 |
|
|
2026
Q1 | $55.2K | Buy |
2,537
+435
| +21% | +$8.42K | ﹤0.01% | 1935 |
|
|
2025
Q4 | $45.2K | Buy |
2,102
+86
| +4% | +$1.81K | ﹤0.01% | 1892 |
|
|
2025
Q3 | $38.8K | Buy |
2,016
+1,256
| +165% | +$22.4K | ﹤0.01% | 1915 |
|
|
2025
Q2 | $13K | Sell |
760
-233
| -23% | -$9.94K | ﹤0.01% | 2388 |
|
|
2025
Q1 | $63.6K | Buy |
993
+170
| +21% | +$17.9K | ﹤0.01% | 1502 |
|
|
2024
Q4 | $100K | Sell |
823
-3
| -0.4% | -$368 | ﹤0.01% | 1270 |
|
|
2024
Q3 | $103K | Buy |
826
+140
| +20% | +$19.4K | ﹤0.01% | 1233 |
|
|
2024
Q2 | $108K | Buy |
686
+61
| +10% | +$7.84K | ﹤0.01% | 1147 |
|
|
2024
Q1 | $80.9K | Buy |
625
+17
| +3% | +$2.08K | ﹤0.01% | 1272 |
|
|
2023
Q4 | $58.6K | Sell |
608
-15
| -2% | -$1.44K | ﹤0.01% | 1366 |
|
|
2023
Q3 | $75.5K | Sell |
623
-21
| -3% | -$2.37K | ﹤0.01% | 1209 |
|
|
2023
Q2 | $73.8K | Buy |
644
+478
| +288% | +$61.6K | ﹤0.01% | 1211 |
|
|
2023
Q1 | $22.9K | Buy |
166
+5
| +3% | +$649 | ﹤0.01% | 1767 |
|
|
2022
Q4 | $20.9K | Sell |
161
-280
| -63% | -$32.4K | ﹤0.01% | 1691 |
|
|
2022
Q3 | $49K | Buy |
441
+84
| +24% | +$8.47K | ﹤0.01% | 1276 |
|
|
2022
Q2 | $27K | Sell |
357
-18
| -5% | -$1.32K | ﹤0.01% | 1533 |
|
|
2022
Q1 | $29K | Sell |
375
-106
| -22% | -$8.12K | ﹤0.01% | 1552 |
|
|
2021
Q4 | $43K | Buy |
481
+100
| +26% | +$8.55K | ﹤0.01% | 1404 |
|
|
2021
Q3 | $35K | Buy |
381
+162
| +74% | +$12.5K | ﹤0.01% | 1463 |
|
|
2021
Q2 | $17K | Buy |
219
+39
| +22% | +$2.96K | ﹤0.01% | 1771 |
|
|
2021
Q1 | $13K | Buy |
180
+108
| +150% | +$9.97K | ﹤0.01% | 1815 |
|
|
2020
Q4 | $12K | Sell |
72
-8
| -10% | -$1.19K | ﹤0.01% | 1719 |
|
|
2020
Q3 | $11K | Hold |
80
| – | – | ﹤0.01% | 1704 |
|
|
2020
Q2 | $12K | Sell |
80
-2
| -2% | -$272 | ﹤0.01% | 1653 |
|
|
2020
Q1 | $8K | Buy |
82
+30
| +58% | +$3.43K | ﹤0.01% | 1732 |
|
|
2019
Q4 | $7K | Buy |
52
+14
| +37% | +$1.41K | ﹤0.01% | 1875 |
|
|
2019
Q3 | $3K | Sell |
38
-43
| -53% | -$5.08K | ﹤0.01% | 2093 |
|
|
2019
Q2 | $12K | Sell |
81
-8
| -9% | -$972 | ﹤0.01% | 1520 |
|
|
2019
Q1 | $11K | Buy |
89
+38
| +75% | +$4.88K | ﹤0.01% | 1498 |
|
|
2018
Q4 | $5K | Buy |
51
+12
| +31% | +$1.5K | ﹤0.01% | 1613 |
|
|
2018
Q3 | $6K | Buy |
39
+10
| +34% | +$1.37K | ﹤0.01% | 1678 |
|
|
2018
Q2 | $3K | Hold |
29
| – | – | ﹤0.01% | 1769 |
|
|
2018
Q1 | $2K | Hold |
29
| – | – | ﹤0.01% | 1880 |
|
|
2017
Q4 | $2K | Hold |
29
| – | – | ﹤0.01% | 1885 |
|
|
2017
Q3 | $2K | Sell |
29
-300
| -91% | -$12K | ﹤0.01% | 1888 |
|
|
2017
Q2 | $13K | Buy |
329
+300
| +1,034% | +$9.77K | ﹤0.01% | 1206 |
|
|
2017
Q1 | $1K | Buy |
+29
| New | +$898 | ﹤0.01% | 1918 |
|
Other funds holding SRPT
EAM
Parallel Advisors's SRPT Position: Q2 2026 in Review
Parallel Advisors reduced its Sarepta Therapeutics (SRPT) stake by 19% in Q2 2026, selling an estimated $9.29K and leaving 2,046 shares worth $36.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2328.
Parallel Advisors first reported a position in SRPT in Q1 2017 and has held it in 38 quarters since. The position peaked at $108K in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Parallel Advisors held 2,046 shares of Sarepta Therapeutics worth $36.8K as of Q2 2026.
- Parallel Advisors sold 491 Sarepta Therapeutics shares in Q2 2026, an estimated $9.29K.
- Sarepta Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2328 holding.
- Parallel Advisors first reported a position in Sarepta Therapeutics in Q1 2017 and has held it in 38 quarters since.
- Parallel Advisors's Sarepta Therapeutics position peaked at $108K in Q2 2024.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.